市場調査レポート

商品コード

1419609

尿路がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Urinary Tract Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月01日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 222 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の尿路がんの市場規模は、2023年に21億1,000万米ドル、2031年に65億5,000万米ドルに達し、2024年～2031年の予測期間にCAGRで15.21%の成長が見込まれています。尿路がんの有病率の上昇、革新的な治療法、診断法の進歩、認知度の向上とスクリーニングへの取り組み、老年人口の増加、併用療法の採用などのさまざまな要因が世界の尿路がん市場を後押ししています。

世界の人々の高齢化が進み、ライフスタイルの要因が持続する中、尿路がんと診断される人の数が増加しています。革新的な治療法も市場拡大の促進要因となっています。ここ数年、標的療法、免疫療法、精密医療アプローチの開発が目覚ましく進行しており、より効果的で低侵襲性の治療オプションが提供されています。これらのブレークスルーは世界の尿路がん市場の成長に大きく寄与しています。分子マーカーや非侵襲性の診断検査の開発により早期発見が可能になり、タイムリーな介入とよりよい治療成績が得られるようになっています。

公衆衛生キャンペーンや政府の取り組みを含む認知度向上とスクリーニングの取り組みは、患者の転帰改善に不可欠な尿路がんの早期診断に寄与しています。高齢者はこれらのがんのリスクが高いため、人口動態の高齢化も重要な促進要因となっています。人口動態と医療支出の増加は、治療に対する需要をさらに高めます。製薬企業やバイオテクノロジー企業による研究開発への投資は、新たな治療オプションや併用療法の発見に役立っています。その結果、先進国市場と新興国市場の両方で医療インフラが拡大し、アクセスが改善されたことで、患者は診断、治療、支持療法をより受けやすくなり、世界の尿路がん市場を後押ししています。

尿路がんの有病率の増加

世界の尿路がんの有病率の増加は、世界の尿路がん市場の主な成長促進要因です。世界規模では、症例の絶対数を考慮すると、膀胱がんは10番目に有病率の高いがんと位置付けられています。男性では、膀胱がんは6番目に多いがんです。腎臓がん（腎がんまたは腎細胞がんとも呼ばれる）は、世界で14番目に多く診断されるがんです。特に男性では9番目、女性では14番目に多いがんです。喫煙、特定の化学品への暴露、不健康な食習慣などの要因が、これらのがんの有病率を高めています。

症例数の増加は、診断ツール、革新的な治療アプローチ、この分野の研究開発に対する需要の高まりにつながっています。需要の急増は、製薬企業、医療機器メーカー、医療提供者に、改良された診断法、標的療法、支持療法を開発し提供する機会を生み出し、世界の尿路がん市場を押し上げています。その結果、尿路がん負担の増大に伴う医療ニーズの進化に対応するため、市場は拡大する見込みです。

研究開発の拡大

著名企業は、尿路がんに対する先進のスクリーニング法の開発に特に重点を置き、研究開発と技術革新に多額の投資を行っています。こうした投資は世界の尿路がん市場に大きな影響を与えています。分子マーカーや非侵襲性の診断検査などの最先端のスクリーニング技術を導入することで、これらの企業は患者の転帰を改善する上で極めて重大な要因である早期発見と早期診断に寄与しています。積極的なアプローチは早期介入の可能性を高め、より効果的で効率的な治療法の開発につながります。結果として、患者の治療と予後にプラスの影響を与えながら、尿路がん市場の成長と将来性を強化することになります。

例えば、2023年3月、バーミンガム大学の研究者とリキッドバイオプシーによるがん検出・スクリーニング企業Nonacusとの提携により、膀胱がんを非侵襲的に同定する革新的な検査法が開発されました。この画期的な検査法は、欧州泌尿器科学会（European Association of Urology）の年次総会で、GALEAS Bladderという名称で正式に発表されました。尿サンプルを利用するこの分子検査は、迅速かつ正確に膀胱がんを検出する手段を提供し、診断プロセスを強化すると同時に、侵襲的な膀胱鏡検査の必要性を最小化します。

当レポートでは、世界の尿路がん市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。

市場規模と予測
- 金額
- 数量
タイプ別
- 腎臓がん
- 膀胱がん
- 尿管がん、腎盂がん
- 尿道がん
モダリティ別
- 診断
- 治療
エンドユーザー別
- 病院
- 外来手術センター
- 専門クリニック
- 薬局
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
市場シェア：企業別（2023年）

第5章世界の尿路がん市場の見通し：地域別（2017年～2031年）

北米
- 市場規模と予測
- タイプ別
- モダリティ別
- エンドユーザー別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
南米
- ブラジル
- アルゼンチン
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第6章市場マッピング（2023年）

タイプ別
モダリティ別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入の分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制枠組みとイノベーション

臨床試験
特許情勢
規制当局の承認
イノベーション/新技術

第10章主要企業情勢

マーケットリーダー上位5社の競合マトリクス
マーケットリーダー上位5社の市場収益分析（2023年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場参入企業5社）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Bristol-Myers Squibb Company
Novartis AG
Merck & Co., Inc.
Exelixis, Inc.
AstraZeneca plc
Astellas Pharma Inc.
Johnson & Johnson Innovative Medicine
Bayer AG
Pfizer, Inc.
Seagen Inc.

第14章戦略的推奨事項

第15章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 2. Global Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 3. Global Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 4. Global Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 5. Global Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 6. Global Urinary Tract Cancer Market Share (%), By Region, 2017-2031F
Figure 7. North America Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 8. North America Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 9. North America Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 10. North America Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 11. North America Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 12. North America Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
Figure 13. United States Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 14. United States Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 15. United States Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 16. United States Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 17. United States Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 18. Canada Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 19. Canada Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 20. Canada Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 21. Canada Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 22. Canada Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 23. Mexico Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 24. Mexico Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 25. Mexico Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 26. Mexico Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 27. Mexico Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 28. Europe Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 29. Europe Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 30. Europe Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 31. Europe Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 32. Europe Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 33. Europe Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
Figure 34. Germany Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 35. Germany Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 36. Germany Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 37. Germany Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 38. Germany Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 39. France Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 40. France Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 41. France Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 42. France Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 43. France Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 44. Italy Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 45. Italy Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 46. Italy Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 47. Italy Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 48. Italy Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 49. United Kingdom Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 50. United Kingdom Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 51. United Kingdom Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 52. United Kingdom Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 53. United Kingdom Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 54. Russia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 55. Russia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 56. Russia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 57. Russia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 58. Russia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 59. Netherlands Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 60. Netherlands Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 61. Netherlands Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 62. Netherlands Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 63. Netherlands Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 64. Spain Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 65. Spain Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 66. Spain Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 67. Spain Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 68. Spain Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 69. Turkey Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 70. Turkey Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 71. Turkey Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 72. Turkey Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 73. Turkey Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 74. Poland Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 75. Poland Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 76. Poland Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 77. Poland Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 78. Poland Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 79. South America Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 80. South America Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 81. South America Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 82. South America Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 83. South America Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 84. South America Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
Figure 85. Brazil Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 86. Brazil Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 87. Brazil Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 88. Brazil Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 89. Brazil Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 90. Argentina Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 91. Argentina Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 92. Argentina Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 93. Argentina Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 94. Argentina Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 95. Asia-Pacific Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 96. Asia-Pacific Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 97. Asia-Pacific Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 98. Asia-Pacific Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 99. Asia-Pacific Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 100. Asia-Pacific Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
Figure 101. India Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 102. India Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 103. India Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 104. India Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 105. India Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 106. China Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 107. China Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 108. China Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 109. China Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 110. China Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 111. Japan Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 112. Japan Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 113. Japan Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 114. Japan Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 115. Japan Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 116. Australia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 117. Australia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 118. Australia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 119. Australia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 120. Australia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 121. Vietnam Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 122. Vietnam Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 123. Vietnam Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 124. Vietnam Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 125. Vietnam Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 126. South Korea Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 127. South Korea Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 128. South Korea Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 129. South Korea Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 130. South Korea Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 131. Indonesia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 132. Indonesia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 133. Indonesia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 134. Indonesia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 135. Indonesia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 136. Philippines Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 137. Philippines Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 138. Philippines Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 139. Philippines Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 140. Philippines Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 141. Middle East & Africa Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 142. Middle East & Africa Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 143. Middle East & Africa Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 144. Middle East & Africa Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 145. Middle East & Africa Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 146. Middle East & Africa Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
Figure 147. Saudi Arabia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 148. Saudi Arabia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 149. Saudi Arabia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 150. Saudi Arabia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 151. Saudi Arabia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 152. UAE Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 153. UAE Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 154. UAE Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 155. UAE Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 156. UAE Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 157. South Africa Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
Figure 158. South Africa Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
Figure 159. South Africa Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
Figure 160. South Africa Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
Figure 161. South Africa Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX10924

Global urinary tract cancer market size was valued at USD 2.11 billion in 2023, which is expected to reach USD 6.55 billion in 2031, with a CAGR of 15.21% for the forecast period between 2024 and 2031. Various factors are propelling the global urinary tract cancer market, such as the rising prevalence of urinary tract cancer, innovative treatment methodologies, advancements in diagnostic methods, enhanced awareness and screening efforts, a growing geriatric population, and the adoption of combination therapies.

As the global population continues to age and lifestyle factors persist, the number of individuals being diagnosed with urinary tract cancer is increasing. Innovative treatment methodologies are another driving force behind the market's expansion. Over the past few years, there has been remarkable progress in developing targeted therapies, immunotherapies, and precision medicine approaches, which provide more effective and often less invasive treatment options. These breakthroughs have significantly helped in the growth of global urinary tract cancer market. The development of molecular markers and non-invasive diagnostic tests enables early detection, facilitating timely interventions and better treatment outcomes.

Increased awareness and screening efforts, including public health campaigns and government initiatives are contributing to the early diagnosis of urinary tract cancers, which is essential for improved patient outcomes. The aging demographic is another key driver, as the elderly population is at a higher risk for these cancers. The demographic trend and increasing healthcare expenditure further fuel the demand for treatments. Investment in research and development by pharmaceutical and biotechnology companies is instrumental in discovering novel therapeutic options and combination therapies. Consequently, expanding healthcare infrastructure and improved accessibility in both developed and emerging markets ensures patients have better access to diagnosis, treatment, and supportive care, thus propelling the global urinary tract cancer market forward.

Increasing Prevalence of Urinary Tract Cancer

The increasing global prevalence of urinary tract cancer is a significant driver propelling the growth of global urinary tract cancer market. On a global scale, bladder cancer ranks as the tenth most prevalent type of cancer when considering the absolute number of cases. Among men, bladder cancer stands as the sixth most common cancer. Kidney cancer, alternatively referred to as renal cancer or renal cell adenocarcinoma, holds the rank of being the 14th most frequently diagnosed cancer globally. Specifically, it stands as the ninth most common cancer among men and the 14th most common cancer among women. Factors such as smoking, exposure to certain chemicals, and unhealthy dietary habits contribute to the growing prevalence of these cancers.

The increasing number of cases has led to a growing demand for diagnostic tools, innovative treatment approaches, and research and development in the field. The surge in demand has created opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to develop and offer improved diagnostic methods, targeted therapies, and supportive care, ultimately boosting the global urinary tract cancer market. Consequently, the market is poised for expansion to meet the evolving healthcare needs associated with the growing urinary tract cancer burden.

Expanding Research and Development Endeavors

Prominent companies are significantly investing in research and innovation, with a specific focus on developing advanced screening methods for urinary tract cancers. These investments have a profound impact on the global urinary tract cancer market. By introducing cutting-edge screening techniques, such as molecular markers and non-invasive diagnostic tests, these companies are contributing to early detection and diagnosis, a crucial factor in improving patient outcomes. The proactive approach enhances the prospects for early intervention and leads to the development of more effective and efficient treatments. In turn, it bolsters the growth and potential of the urinary tract cancer market while positively impacting patient care and prognosis.

For instance, in March 2023, the partnership between researchers at the University of Birmingham and the liquid biopsy cancer detection and screening company Nonacus yielded an innovative test for the non-invasive identification of bladder cancer. The breakthrough was officially unveiled at the Annual Meeting of the European Association of Urology under the name GALEAS Bladder. The molecular test, which utilizes urine samples, offers a rapid and precise means of detecting bladder cancer, enhancing the diagnostic process while minimizing the necessity for invasive cystoscopies.

Government Initiatives

Numerous governments across the world have initiated public awareness programs aimed at educating their populations about urinary tract-related disorders and the importance of early detection and prevention. These efforts play a pivotal role in supporting the growth of the global urinary tract cancer market. Through increasing awareness about the risk factors, symptoms, and the need for regular screenings, these programs contribute to the early diagnosis of kidney and urinary tract cancers. Consequently, early detection often leads to more effective treatment options, better patient outcomes, and an increased demand for diagnostic and therapeutic solutions, thereby bolstering the growth prospects of the global urinary tract cancer market. As an example, during September 2023, the American Kidney Fund (AKF) initiated educational awareness initiatives dedicated to two uncommon kidney ailments: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN). These campaigns were sponsored by Novartis, designed to furnish patients with comprehensive knowledge about these conditions and link them with valuable resources, aiding in their comprehension and effective management of these rare kidney diseases.

Growing Demand for Kidney Cancer Treatment Options

Patients, medical practitioners, and healthcare institutions proactively pursue innovative and effective treatment modalities to address the mounting health issue. The global urinary tract cancer market is witnessing significant progress, marked by the advent of targeted therapies and immunotherapies, thereby expanding the therapeutic landscape, and elevating the prognosis for kidney cancer patients. The increase in demand highlights the critical necessity for comprehensive and individualized solutions in the fight against kidney cancer, as part of the broader urinary tract cancer market. As an example, in October 2023, Merck in the United States and Canada, disclosed that the Drug Controller General of India (DCGI) granted approval for Keytruda (pembrolizumab), MSD's anti-PD-1 therapy, to be used in treating renal cell carcinoma in adults.

Emerging Advanced Diagnostic Solutions

Increasing demand for cutting-edge diagnostic solutions is becoming evident in the global urinary tract cancer market. The surge is propelled by various factors, primarily the increasing global prevalence of urinary tract cancer. Both patients and healthcare professionals are progressively pursuing precise, efficient, and less invasive diagnostic approaches to detect these cancers at earlier stages, to enhance treatment outcomes. Advanced diagnostic techniques, including molecular markers and non-invasive tests, offer early detection and reduced reliance on invasive procedures. For instance, Genomictree, a firm specializing in biomarker-driven cancer diagnostics, announced in May 2023 that it launched its bladder cancer diagnostic product, EarlyTect-BCD, in the United States.

Future Market Scenario

The future of global urinary tract cancer market looks promising, with a landscape full of opportunities. The optimistic outlook results from various factors. The continuous progress in research and development which is driving the exploration of innovative treatment modalities, encompassing immunotherapies, precision medicine, and targeted therapies. These emerging therapeutic options offer patients with more effective and less invasive alternatives, ultimately enhancing their quality of life and long-term prognosis.

Also, the increasing incidence of urinary tract cancer, covering bladder and kidney cancers, spurs the demand for diagnostic and treatment solutions. With factors like the growing geriatric population and lifestyle-related risks contributing to its prevalence, the market is poised for expansion. Moreover, increased awareness about early detection and screening, alongside improved healthcare infrastructure and accessibility in developed and emerging markets contribute to the industry's growth. Collectively, these elements are showing a promising future for the global urinary tract cancer market, presenting abundant prospects for research, innovation, and enhanced patient care.

Key Players Landscape and Outlook

Key players are proactively forging sales agreements to optimize the distribution of their products in the global urinary tract cancer market. These agreements broaden the reach and efficiency of their diagnostics, therapies, and medical devices. Partnerships with established distributors or healthcare networks empower these organizations to guarantee effective delivery of their products to healthcare providers and patients, enhancing accessibility and quality of patient care. The approach holds particular significance in urinary tract cancer, where early detection and timely treatment are paramount. Collaborative sales agreements are playing a pivotal role in addressing diagnostic and treatment challenges, ultimately benefiting patients, contributing to the market's expansion.

In August 2023, a synthetic royalty agreement worth USD 500 million was established between Royalty Pharma plc and Ferring Pharmaceuticals, headquartered in Saint-Prex, Switzerland. The agreement involves specified sales of Ferring's novel gene therapy designed for bladder cancer. According to the terms, Royalty Pharma will make an upfront payment of USD 300 million to Ferring and potentially an additional USD 200 million in milestone payments. In return, Royalty Pharma will receive royalties on the sales of Ferring's intravesical gene therapy known as Adstiladrin (nadofaragene firadenovec-vncg).

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Urinary Tract Cancer Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. Value
- 4.1.2. Volume
4.2. By Types
- 4.2.1. Kidney Cancer
- 4.2.2. Bladder Cancer
- 4.2.3. Ureteric and Renal Pelvic Cancer
- 4.2.4. Urethral Cancer
4.3. By Modality
- 4.3.1. Diagnosis
  - 4.3.1.1. Urinalysis
  - 4.3.1.2. Cytology
  - 4.3.1.3. Cystoscopy
  - 4.3.1.4. MRI Scan
  - 4.3.1.5. CT Scan
- 4.3.2. Treatment
  - 4.3.2.1. Surgery
  - 4.3.2.2. Radiation Therapy
  - 4.3.2.3. Radiopharmaceuticals
  - 4.3.2.4. Chemotherapy
  - 4.3.2.5. Immunotherapy
  - 4.3.2.6. Gene Therapy
  - 4.3.2.7. Cryotherapy
  - 4.3.2.8. High-Intensity Focused Ultrasound
4.4. By End-users
- 4.4.1. Hospitals
- 4.4.2. Ambulatory Surgical Centers
- 4.4.3. Specialty Clinics
- 4.4.4. Pharmacies
- 4.4.5. Others
4.5. By Region
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. South America
- 4.5.4. Asia-Pacific
- 4.5.5. Middle East and Africa
4.6. By Company Market Share (%), 2023

5. Global Urinary Tract Cancer Market Outlook, By Region, 2017-2031F

5.1 North America*
- 5.1.1 Market Size & Forecast
  - 5.1.1.1 Value
  - 5.1.1.2 Volume
- 5.1.2 By Types
  - 5.1.2.1 Kidney Cancer
  - 5.1.2.2 Bladder Cancer
  - 5.1.2.3 Ureteric and Renal Pelvic Cancer
  - 5.1.2.4 Urethral Cancer
- 5.1.3 By Modality
  - 5.1.3.1 Diagnosis
  - 5.1.3.1.1 Urinalysis
  - 5.1.3.1.2 Cytology
  - 5.1.3.1.3 Cystoscopy
  - 5.1.3.1.4 MRI Scan
  - 5.1.3.1.5 CT Scan
  - 5.1.3.2 Treatment
  - 5.1.3.2.1 Surgery
  - 5.1.3.2.2 Radiation Therapy
  - 5.1.3.2.3 Radiopharmaceuticals
  - 5.1.3.2.4 Chemotherapy
  - 5.1.3.2.5 Immunotherapy
  - 5.1.3.2.6 Gene Therapy
  - 5.1.3.2.7 Cryotherapy
  - 5.1.3.2.8 High-Intensity Focused Ultrasound
- 5.1.4 By End-users
  - 5.1.4.1 Hospitals
  - 5.1.4.2 Ambulatory Surgical Centers
  - 5.1.4.3 Specialty Clinics
  - 5.1.4.4 Pharmacies
  - 5.1.4.5 Others
- 5.1.5 United States*
  - 5.1.5.1 Market Size & Forecast
  - 5.1.5.1.1 Value
  - 5.1.5.1.2 Volume
  - 5.1.5.2 By Types
  - 5.1.5.2.1 Kidney Cancer
  - 5.1.5.2.2 Bladder Cancer
  - 5.1.5.2.3 Ureteric and Renal Pelvic Cancer
  - 5.1.5.2.4 Urethral Cancer
  - 5.1.5.3 By Modality
  - 5.1.5.3.1 Diagnosis
  - 5.1.5.3.1.1 Urinalysis
  - 5.1.5.3.1.2 Cytology
  - 5.1.5.3.1.3 Cystoscopy
  - 5.1.5.3.1.4 MRI Scan
  - 5.1.5.3.1.5 CT Scan
  - 5.1.5.3.2 Treatment
  - 5.1.5.3.2.1 Surgery
  - 5.1.5.3.2.2 Radiation Therapy
  - 5.1.5.3.2.3 Radiopharmaceuticals
  - 5.1.5.3.2.4 Chemotherapy
  - 5.1.5.3.2.5 Immunotherapy
  - 5.1.5.3.2.6 Gene Therapy
  - 5.1.5.3.2.7 Cryotherapy
  - 5.1.5.3.2.8 High-Intensity Focused Ultrasound
  - 5.1.5.4 By End-users
  - 5.1.5.4.1 Hospitals
  - 5.1.5.4.2 Ambulatory Surgical Centers
  - 5.1.5.4.3 Specialty Clinics
  - 5.1.5.4.4 Pharmacies
  - 5.1.5.4.5 Others
- 5.1.6 Canada
- 5.1.7 Mexico

All segments will be provided for all regions and countries covered:

5.2 Europe
- 5.2.1 Germany
- 5.2.2 France
- 5.2.3 Italy
- 5.2.4 United Kingdom
- 5.2.5 Russia
- 5.2.6 Netherlands
- 5.2.7 Spain
- 5.2.8 Turkey
- 5.2.9 Poland
5.3 South America
- 5.3.1 Brazil
- 5.3.2 Argentina
5.4 Asia-Pacific
- 5.4.1 India
- 5.4.2 China
- 5.4.3 Japan
- 5.4.4 Australia
- 5.4.5 Vietnam
- 5.4.6 South Korea
- 5.4.7 Indonesia
- 5.4.8 Philippines
5.5 Middle East & Africa
- 5.5.1 Saudi Arabia
- 5.5.2 UAE
- 5.5.3 South Africa

6. Market Mapping, 2023

6.1. By Types
6.2. By Modality
6.3. By End-users
6.4. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

10.1 Clinical Trials
10.2 Patent Landscape
10.3 Regulatory Approvals
10.4 Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Bristol-Myers Squibb Company
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. Novartis AG
13.3. Merck & Co., Inc.
13.4. Exelixis, Inc.
13.5. AstraZeneca plc
13.6. Astellas Pharma Inc.
13.7. Johnson & Johnson Innovative Medicine
13.8. Bayer AG
13.9. Pfizer, Inc.
13.10. Seagen Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

尿路がんの世界市場の評価：タイプ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Urinary Tract Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F

尿路がんの有病率の増加

研究開発の拡大

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の尿路がん市場の見通し（2017年～2031年）

第5章 世界の尿路がん市場の見通し：地域別（2017年～2031年）

第6章 市場マッピング（2023年）

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要企業情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的推奨事項

第15章 当社について、免責事項